menu
    • menu
    [{"orgOrder":0,"company":"HEC Group","sponsor":"Lannett","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Insulin aspart","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"HEC Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HEC Group \/ Lannett","highestDevelopmentStatusID":"1","companyTruncated":"HEC Group \/ Lannett"},{"orgOrder":0,"company":"HEC Group","sponsor":"Lannett Company, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"HEC Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HEC Group \/ HEC Group","highestDevelopmentStatusID":"12","companyTruncated":"HEC Group \/ HEC Group"}]

    Find Clinical Drug Pipeline Developments & Deals by HEC Group

    Menu

    HEC Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HEC Group

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            HEC Group

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Recipient : Lannett Company, Inc.

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lannett Announces Subject Dosing Complete For Pivotal Clinical Trial Of Biosimilar Insulin Glargine

                            Details : Biosimilar insulin glargine is the most significant opportunity in the company's current pipeline. Recent estimated U.S. sales of long acting insulin glargine (Glaricon) are approximately $10 billion annually, according to IQVIA, although manufacturer re...

                            Brand Name : Glaricon

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            August 31, 2022

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Recipient : Lannett Company, Inc.

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HEC Group

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            HEC Group

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin aspart

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Lannett

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin

                            Details : The biosimilar insulin aspart is currently in development and Lannett will help manage the remaining clinical and regulatory steps specific for a U.S. Food and Drug Administration (FDA) approval to market the product.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            February 09, 2021

                            Lead Product(s) : Insulin aspart

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Lannett

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth